Tuningthe Structural Properties of a Single-DomainAntibody Scaffold for Improved Fibroblast Activation Protein Targeting

MOLECULAR PHARMACEUTICS · Published 2026-07-21 · DOI 10.1021/acs.molpharmaceut.6c00238

Free full text

Authors (12)

Joseph P. Gallant, Kendahl L. Ott, Ohyun Kwon, Adedamola Adeniyi, Kendall E. Barrett, Zachary T. Rosenkrans, Jason C. Mixdorf, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Reinier Hernandez, Bryan P. Bednarz, Aaron M. LeBeau

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Gallant, J., Ott, K., Kwon, O., et al. (2026). Tuningthe Structural Properties of a Single-DomainAntibody Scaffold for Improved Fibroblast Activation Protein Targeting. MOLECULAR PHARMACEUTICS. https://doi.org/10.1021/acs.molpharmaceut.6c00238

Related articles

• A CosmeticProduct Containing PEG Derivatives InducesAnti-PEG IgM Mainly through Stimulation of the Spleen Cells in Mice · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• [68Ga]Ga-DOTA-DP-UBI 29-41: A Novel 68Ga-LabeledUbiquicidin 29-41 Derivative Containing d -Prolinefor Bacterial Infection PET Imaging · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• PreclinicalEvaluation of 177Lu-LabeledAnti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Development of [111In]In-CHX-A″-DTPA-αCD68for ImmunoSPECT to Image Murine Macrophages · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• IntegratingTumor Targeting and Half-Life Extensioninto a Dual-Surfaced Single-Domain ADAPT Protein · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• AutomatedRadiosynthesis of High-Molar-Activity 4-Borono-2-[18F]Fluorophenylalanine: Validation in Rodent Tumor Modelsand Nonhuman Primates · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Evaluationof 161Tb-Labeled DOTA-Ibandronatefor Targeted Radionuclide Therapy in Bone Metastases · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Predicting pHmax and Salt DisproportionationRisk for Basic Drugs · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• PreclinicalEvaluation of [68Ga]Ga-CS03as a Novel GPC3-Targeted Probe for Imaging GPC3 in HepatocellularCarcinoma Models · MOLECULAR PHARMACEUTICS · 2026 · Same journal